{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,29]],"date-time":"2024-07-29T02:28:55Z","timestamp":1722220135232},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2013,10,21]],"date-time":"2013-10-21T00:00:00Z","timestamp":1382313600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2013,12]]},"DOI":"10.1186\/1471-2407-13-489","type":"journal-article","created":{"date-parts":[[2013,10,21]],"date-time":"2013-10-21T11:01:18Z","timestamp":1382353278000},"source":"Crossref","is-referenced-by-count":5,"title":["An explorative analysis of ERCC1-19q13 copy number aberrations in a chemonaive stage III colorectal cancer cohort"],"prefix":"10.1186","volume":"13","author":[{"given":"David Hersi","family":"Smith","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ib Jarle","family":"Christensen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Niels Frank","family":"Jensen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bo","family":"Markussen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sven","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans J\u00f8rgen","family":"Nielsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nils","family":"Br\u00fcnner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kirsten Vang","family":"Nielsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,10,21]]},"reference":[{"key":"5266_CR1","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1124\/mol.58.5.920","volume":"58","author":"JM Woynarowski","year":"2000","unstructured":"Woynarowski JM, Faivre S, Herzig MC, Arnett B, Chapman WG, Trevino AV, et al: Oxaliplatin-induced damage of cellular DNA. Mol Pharmacol. 2000, 58: 920-927.","journal-title":"Mol Pharmacol"},{"key":"5266_CR2","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.ctrv.2006.09.006","volume":"33","author":"CA Rabik","year":"2007","unstructured":"Rabik CA, Dolan ME: Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat Rev. 2007, 33: 9-23. 10.1016\/j.ctrv.2006.09.006.","journal-title":"Cancer Treat Rev"},{"key":"5266_CR3","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1158\/1078-0432.CCR-07-2238","volume":"14","author":"LP Martin","year":"2008","unstructured":"Martin LP, Hamilton TC, Schilder RJ: Platinum resistance: the role of DNA repair pathways. Clin Cancer Res. 2008, 14: 1291-1295. 10.1158\/1078-0432.CCR-07-2238.","journal-title":"Clin Cancer Res"},{"key":"5266_CR4","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1146\/annurev.bi.65.070196.001031","volume":"65","author":"RD Wood","year":"1996","unstructured":"Wood RD: DNA repair in eukaryotes. Annu Rev Biochem. 1996, 65: 135-167. 10.1146\/annurev.bi.65.070196.001031.","journal-title":"Annu Rev Biochem"},{"key":"5266_CR5","doi-asserted-by":"publisher","first-page":"5776","DOI":"10.1128\/MCB.24.13.5776-5787.2004","volume":"24","author":"LJ Niedernhofer","year":"2004","unstructured":"Niedernhofer LJ, Odijk H, Budzowska M, van DE, Maas A, Theil AF, et al: The structure-specific endonuclease Ercc1-Xpf is required to resolve DNA interstrand cross-link-induced double-strand breaks. Mol Cell Biol. 2004, 24: 5776-5787. 10.1128\/MCB.24.13.5776-5787.2004.","journal-title":"Mol Cell Biol"},{"key":"5266_CR6","doi-asserted-by":"crossref","first-page":"4298","DOI":"10.1200\/JCO.2001.19.23.4298","volume":"19","author":"Y Shirota","year":"2001","unstructured":"Shirota Y, Stoehlmacher J, Brabender J, Xiong YP, Uetake H, Danenberg KD, et al: ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy. J Clin Oncol. 2001, 19: 4298-4304.","journal-title":"J Clin Oncol"},{"key":"5266_CR7","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1016\/j.ejca.2009.04.017","volume":"45","author":"M Koopman","year":"2009","unstructured":"Koopman M, Venderbosch S, van TH, Ligtenberg MJ, Nagtegaal I, Van Krieken JH, et al: Predictive and prognostic markers for the outcome of chemotherapy in advanced colorectal cancer, a retrospective analysis of the phase III randomised CAIRO study. Eur J Cancer. 2009, 45: 1999-2006. 10.1016\/j.ejca.2009.04.017.","journal-title":"Eur J Cancer"},{"key":"5266_CR8","doi-asserted-by":"publisher","first-page":"2690","DOI":"10.1200\/JCO.2007.15.5580","volume":"26","author":"MS Braun","year":"2008","unstructured":"Braun MS, Richman SD, Quirke P, Daly C, Adlard JW, Elliott F, et al: Predictive biomarkers of chemotherapy efficacy in colorectal cancer: results from the UK MRC FOCUS trial. J Clin Oncol. 2008, 26: 2690-2698. 10.1200\/JCO.2007.15.5580.","journal-title":"J Clin Oncol"},{"key":"5266_CR9","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1097\/COC.0b013e31817be58e","volume":"32","author":"SH Kim","year":"2009","unstructured":"Kim SH, Kwon HC, Oh SY, Lee DM, Lee S, Lee JH, et al: Prognostic value of ERCC1, thymidylate synthase, and glutathione S-transferase pi for 5-FU\/oxaliplatin chemotherapy in advanced colorectal cancer. Am J Clin Oncol. 2009, 32: 38-43. 10.1097\/COC.0b013e31817be58e.","journal-title":"Am J Clin Oncol"},{"key":"5266_CR10","doi-asserted-by":"publisher","first-page":"6831","DOI":"10.1158\/0008-5472.CAN-09-1237","volume":"69","author":"NR Bhagwat","year":"2009","unstructured":"Bhagwat NR, Roginskaya VY, Acquafondata MB, Dhir R, Wood RD, Niedernhofer LJ: Immunodetection of DNA repair endonuclease ERCC1-XPF in human tissue. Cancer Res. 2009, 69: 6831-6838. 10.1158\/0008-5472.CAN-09-1237.","journal-title":"Cancer Res"},{"key":"5266_CR11","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/1472-6750-12-88","volume":"12","author":"D Ma","year":"2012","unstructured":"Ma D, Baruch D, Shu Y, Yuan K, Sun Z, Ma K, et al: Using protein microarray technology to screen anti-ERCC1 monoclonal antibodies for specificity and applications in pathology. BMC Biotechnol. 2012, 12: 88-10.1186\/1472-6750-12-88.","journal-title":"BMC Biotechnol"},{"key":"5266_CR12","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/S0304-3835(99)00390-0","volume":"151","author":"JJ Yu","year":"2000","unstructured":"Yu JJ, Bicher A, Ma YK, Bostick-Bruton F, Reed E: Absence of evidence for allelic loss or allelic gain for ERCC1 or for XPD in human ovarian cancer cells and tissues. Cancer Lett. 2000, 151: 127-132. 10.1016\/S0304-3835(99)00390-0.","journal-title":"Cancer Lett"},{"key":"5266_CR13","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/BF01054765","volume":"26","author":"BC Liang","year":"1995","unstructured":"Liang BC, Ross DA, Reed E: Genomic copy number changes of DNA repair genes ERCC1 and ERCC2 in human gliomas. J Neurooncol. 1995, 26: 17-23. 10.1007\/BF01054765.","journal-title":"J Neurooncol"},{"key":"5266_CR14","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/j.cllc.2013.01.006","volume":"14","author":"E Vanhecke","year":"2013","unstructured":"Vanhecke E, Valent A, Tang X, Vielh P, Friboulet L, Tang T, et al: 19q13-ERCC1 Gene copy number increase in non-small-cell lung cancer. Clin Lung Cancer. 2013, 14: 549-557. 10.1016\/j.cllc.2013.01.006.","journal-title":"Clin Lung Cancer"},{"key":"5266_CR15","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1093\/jnci\/djq528","volume":"103","author":"KV Nielsen","year":"2011","unstructured":"Nielsen KV, Brunner N: Re: topoisomerase II alpha and responsiveness of breast cancer to adjuvant chemotherapy. J Natl Cancer Inst. 2011, 103: 352-353. 10.1093\/jnci\/djq528.","journal-title":"J Natl Cancer Inst"},{"key":"5266_CR16","doi-asserted-by":"publisher","first-page":"e60613","DOI":"10.1371\/journal.pone.0060613","volume":"8","author":"DH Smith","year":"2013","unstructured":"Smith DH, Christensen IJ, Jensen NF, Markussen B, Romer MU, Nygard SB, et al: Mechanisms of topoisomerase I (TOP1) gene copy number increase in a stage III colorectal cancer patient cohort. PLoS One. 2013, 8: e60613-10.1371\/journal.pone.0060613.","journal-title":"PLoS One"},{"issue":"1","key":"5266_CR17","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.molonc.2012.09.001","volume":"7","author":"MU Romer","year":"2012","unstructured":"Romer MU, Nygard SB, Christensen IJ, Nielsen SL, Nielsen KV, Muller S, et al: Topoisomerase 1(TOP1) gene copy number in stage III colorectal cancer patients and its relation to prognosis. Mol Oncol. 2012, 7 (1): 101-111.","journal-title":"Mol Oncol"},{"key":"5266_CR18","first-page":"227","volume-title":"GI Cancer","author":"HJ Nielsen","year":"1998","unstructured":"Nielsen HJ, McArdle C, Moesgaard F, The RANX05 Study Group: The effect of ranitidine on long-term survival on primary colorectal cancer. A 40 months interim analysis. GI Cancer. 1998, 227-233."},{"key":"5266_CR19","doi-asserted-by":"publisher","first-page":"e40675","DOI":"10.1371\/journal.pone.0040675","volume":"7","author":"SH Matthiesen","year":"2012","unstructured":"Matthiesen SH, Hansen CM: Fast and non-toxic in situ hybridization without blocking of repetitive sequences. PLoS One. 2012, 7: e40675-10.1371\/journal.pone.0040675.","journal-title":"PLoS One"},{"key":"5266_CR20","first-page":"8634","volume":"63","author":"AV Roschke","year":"2003","unstructured":"Roschke AV, Tonon G, Gehlhaus KS, McTyre N, Bussey KJ, Lababidi S, et al: Karyotypic complexity of the NCI-60 drug-screening panel. Cancer Res. 2003, 63: 8634-8647.","journal-title":"Cancer Res"},{"key":"5266_CR21","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1002\/(SICI)1098-2264(200002)27:2<183::AID-GCC10>3.0.CO;2-P","volume":"27","author":"BM Ghadimi","year":"2000","unstructured":"Ghadimi BM, Sackett DL, Difilippantonio MJ, Schrock E, Neumann T, Jauho A, et al: Centrosome amplification and instability occurs exclusively in aneuploid, but not in diploid colorectal cancer cell lines, and correlates with numerical chromosomal aberrations. Genes Chromosomes Cancer. 2000, 27: 183-190. 10.1002\/(SICI)1098-2264(200002)27:2<183::AID-GCC10>3.0.CO;2-P.","journal-title":"Genes Chromosomes Cancer"},{"key":"5266_CR22","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1038\/nature11252","volume":"487","author":"The Cancer Genome Atlas Network","year":"2012","unstructured":"The Cancer Genome Atlas Network: Comprehensive molecular characterization of human colon and rectal cancer. Nature. 2012, 487: 330-337. 10.1038\/nature11252.","journal-title":"Nature"},{"key":"5266_CR23","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1046\/j.1365-2559.2003.01720.x","volume":"43","author":"T Knosel","year":"2003","unstructured":"Knosel T, Schluns K, Stein U, Schwabe H, Schlag PM, Dietel M, et al: Genetic imbalances with impact on survival in colorectal cancer patients. Histopathology. 2003, 43: 323-331. 10.1046\/j.1365-2559.2003.01720.x.","journal-title":"Histopathology"},{"key":"5266_CR24","doi-asserted-by":"publisher","first-page":"20007","DOI":"10.1073\/pnas.0710052104","volume":"104","author":"R Beroukhim","year":"2007","unstructured":"Beroukhim R, Getz G, Nghiemphu L, Barretina J, Hsueh T, Linhart D, et al: Assessing the significance of chromosomal aberrations in cancer: methodology and application to glioma. Proc Natl Acad Sci USA. 2007, 104: 20007-20012. 10.1073\/pnas.0710052104.","journal-title":"Proc Natl Acad Sci USA"},{"key":"5266_CR25","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1038\/nature07179","volume":"455","author":"R Firestein","year":"2008","unstructured":"Firestein R, Bass AJ, Kim SY, Dunn IF, Silver SJ, Guney I, et al: CDK8 is a colorectal cancer oncogene that regulates beta-catenin activity. Nature. 2008, 455: 547-551. 10.1038\/nature07179.","journal-title":"Nature"},{"key":"5266_CR26","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1002\/(SICI)1097-0215(19991022)84:5<533::AID-IJC16>3.0.CO;2-J","volume":"84","author":"AM Bamberger","year":"1999","unstructured":"Bamberger AM, Methner C, Lisboa BW, Stadtler C, Schulte HM, Loning T, et al: Expression pattern of the AP-1 family in breast cancer: association of fosB expression with a well-differentiated, receptor-positive tumor phenotype. Int J Cancer. 1999, 84: 533-538. 10.1002\/(SICI)1097-0215(19991022)84:5<533::AID-IJC16>3.0.CO;2-J.","journal-title":"Int J Cancer"},{"key":"5266_CR27","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1002\/mc.20528","volume":"48","author":"MJ Laska","year":"2009","unstructured":"Laska MJ, Lowe SW, Zender L, Hearn S, Vogel U, Jensen UB, et al: Enforced expression of PPP1R13L increases tumorigenesis and invasion through p53-dependent and p53-independent mechanisms. Mol Carcinog. 2009, 48: 832-842. 10.1002\/mc.20528.","journal-title":"Mol Carcinog"},{"key":"5266_CR28","doi-asserted-by":"publisher","first-page":"6299","DOI":"10.1038\/sj.onc.1207838","volume":"23","author":"WC Sin","year":"2004","unstructured":"Sin WC, Zhang Y, Zhong W, Adhikarakunnathu S, Powers S, Hoey T, et al: G protein-coupled receptors GPR4 and TDAG8 are oncogenic and overexpressed in human cancers. Oncogene. 2004, 23: 6299-6303. 10.1038\/sj.onc.1207838.","journal-title":"Oncogene"},{"key":"5266_CR29","doi-asserted-by":"publisher","first-page":"2581","DOI":"10.1038\/sj.onc.1206336","volume":"22","author":"A Beghini","year":"2003","unstructured":"Beghini A, Magnani I, Roversi G, Piepoli T, Di TS, Moroni RF, et al: The neural progenitor-restricted isoform of the MARK4 gene in 19q13.2 is upregulated in human gliomas and overexpressed in a subset of glioblastoma cell lines. Oncogene. 2003, 22: 2581-2591. 10.1038\/sj.onc.1206336.","journal-title":"Oncogene"},{"key":"5266_CR30","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1126\/science.290.5493.989","volume":"290","author":"L Zhang","year":"2000","unstructured":"Zhang L, Yu J, Park BH, Kinzler KW, Vogelstein B: Role of BAX in the apoptotic response to anticancer agents. Science. 2000, 290: 989-992. 10.1126\/science.290.5493.989.","journal-title":"Science"},{"key":"5266_CR31","doi-asserted-by":"publisher","first-page":"5527","DOI":"10.1038\/sj.onc.1209541","volume":"25","author":"N Leung","year":"2006","unstructured":"Leung N, Turbide C, Olson M, Marcus V, Jothy S, Beauchemin N: Deletion of the carcinoembryonic antigen-related cell adhesion molecule 1 (Ceacam1) gene contributes to colon tumor progression in a murine model of carcinogenesis. Oncogene. 2006, 25: 5527-5536. 10.1038\/sj.onc.1209541.","journal-title":"Oncogene"},{"key":"5266_CR32","doi-asserted-by":"publisher","first-page":"9306","DOI":"10.1038\/sj.onc.1208259","volume":"23","author":"S Nittka","year":"2004","unstructured":"Nittka S, Gunther J, Ebisch C, Erbersdobler A, Neumaier M: The human tumor suppressor CEACAM1 modulates apoptosis and is implicated in early colorectal tumorigenesis. Oncogene. 2004, 23: 9306-9313. 10.1038\/sj.onc.1208259.","journal-title":"Oncogene"},{"key":"5266_CR33","doi-asserted-by":"publisher","first-page":"20315","DOI":"10.1073\/pnas.0810715105","volume":"105","author":"PG Rychahou","year":"2008","unstructured":"Rychahou PG, Kang J, Gulhati P, Doan HQ, Chen LA, Xiao SY, et al: Akt2 overexpression plays a critical role in the establishment of colorectal cancer metastasis. Proc Natl Acad Sci USA. 2008, 105: 20315-20320. 10.1073\/pnas.0810715105.","journal-title":"Proc Natl Acad Sci USA"},{"key":"5266_CR34","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1515\/BC.2008.173","volume":"389","author":"CK Kontos","year":"2008","unstructured":"Kontos CK, Papadopoulos IN, Scorilas A: Quantitative expression analysis and prognostic significance of the novel apoptosis-related gene BCL2L12 in colon cancer. Biol Chem. 2008, 389: 1467-1475.","journal-title":"Biol Chem"},{"key":"5266_CR35","first-page":"e37","volume":"12","author":"S Bulow","year":"2010","unstructured":"Bulow S, Harling H, Iversen LH, Ladelund S: Improved survival after rectal cancer in Denmark. Colorectal Dis. 2010, 12: e37-e42.","journal-title":"Colorectal Dis"},{"key":"5266_CR36","doi-asserted-by":"publisher","first-page":"7518","DOI":"10.1200\/JCO.2005.00.471","volume":"23","author":"A Russo","year":"2005","unstructured":"Russo A, Bazan V, Iacopetta B, Kerr D, Soussi T, Gebbia N: The TP53 colorectal cancer international collaborative study on the prognostic and predictive significance of p53 mutation: influence of tumor site, type of mutation, and adjuvant treatment. J Clin Oncol. 2005, 23: 7518-7528. 10.1200\/JCO.2005.00.471.","journal-title":"J Clin Oncol"},{"key":"5266_CR37","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1016\/j.ygyno.2012.05.006","volume":"126","author":"JA Deloia","year":"2012","unstructured":"Deloia JA, Bhagwat NR, Darcy KM, Strange M, Tian C, Nuttall K, et al: Comparison of ERCC1\/XPF genetic variation, mRNA and protein levels in women with advanced stage ovarian cancer treated with intraperitoneal platinum. Gynecol Oncol. 2012, 126: 448-454. 10.1016\/j.ygyno.2012.05.006.","journal-title":"Gynecol Oncol"},{"key":"5266_CR38","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1200\/JCO.2006.09.2775","volume":"25","author":"AC Wolff","year":"2007","unstructured":"Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, et al: American society of clinical oncology\/college of American pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol. 2007, 25: 118-145.","journal-title":"J Clin Oncol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-13-489.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-2407-13-489\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-13-489","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,31]],"date-time":"2019-07-31T01:42:33Z","timestamp":1564537353000},"score":1,"resource":{"primary":{"URL":"http:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/1471-2407-13-489"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,10,21]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["5266"],"URL":"https:\/\/doi.org\/10.1186\/1471-2407-13-489","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,10,21]]},"article-number":"489"}}